Evaluation of 177Lu-CHX-A′′-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers
Mythili Kameswaran(Tata Memorial Hospital), Ashutosh Dash(Bhabha Atomic Research Centre), Naresh Gamre(Bhabha Atomic Research Centre), Usha Pandey(Bhabha Atomic Research Centre), Haladhar Dev Sarma(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre)
Cited by 12
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99